2-((4-(trifluoromethyl)benzyl)oxy)acetic acid | 602262-41-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-((4-(trifluoromethyl)benzyl)oxy)acetic acid
• 英文别名: 2-[[4-(trifluoromethyl)phenyl]methoxy]acetic acid
• CAS: 602262-41-9
• 化学式: C₁₀H₉F₃O₃
• 分子量: 234.175
• InChiKey: SXWYDCAACSVYPS-UHFFFAOYSA-N

物化性质

• 沸点：
  325.8±37.0 °C(Predicted)
• 密度：
  1.351±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  2-((4-(trifluoromethyl)benzyl)oxy)acetic acid 在 草酰氯 、 三乙胺 、 lithium hydroxide 作用下， 以 四氢呋喃 、 二氯甲烷 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 3.0h， 生成
  参考文献：
  名称：

  Discovery of 1,4-Benzodiazepine-2,5-dione (BZD) Derivatives as Dual Nucleotide Binding Oligomerization Domain Containing 1/2 (NOD1/NOD2) Antagonists Sensitizing Paclitaxel (PTX) To Suppress Lewis Lung Carcinoma (LLC) Growth in Vivo

  摘要：

  Nucleotide-binding oligomerization domain-like receptors (NLRs) are intracellular sensors of pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs). Previously, we reported nucleotide-binding oligomerization domain-containing protein 1 (NOD1) antagonists (II, 12) and a NOD2 antagonist (9) that sensitized docetaxel (DTX) or paclitaxel (PTX) treatment for breast or lung cancer. In this article, we describe for the first time a 1,4-benzodiazepine-2,5-dione (BZD) derivative (26bh) that acts as a dual NOD1/NOD2 antagonist and inhibits both nuclear factor kappa B (NF-kappa B) and mitogen-activated protein kinase (MAPK) inflammatory signaling, thereby sensitizing PTX to suppress Lewis lung carcinoma (LLC) growth. After investigation of the compound's cytotoxicity, a systematic structure-activity relationship (SAR) was completed and revealed several key factors that were necessary to maintain antagonistic ability. This study establishes the possibility for using adjuvant treatment to combat cancer by antagonizing both NOD1 and NOD2 signaling.

  DOI：

  10.1021/acs.jmedchem.7b00608
• 作为产物：
  描述：

  4-(三氟甲基)苄醇 、 溴乙酸 在 sodium hydride 、 四丁基碘化铵 作用下， 以 四氢呋喃 、 mineral oil 为溶剂， 反应 3.5h， 生成 2-((4-(trifluoromethyl)benzyl)oxy)acetic acid
  参考文献：
  名称：

  苄基炔基醚的 [3,3]-Sigmatropic 重排/5-exo-dig 环化反应：取代的 2-茚酮和茚的合成

  摘要：

  取代的苄基的炔醚，从在两步骤序列相应的α -烷氧基酮涉及烯醇三氟甲磺酸形成和KO制备吨卜诱导E2消除，经历[3,3] -sigmatropic重排/分子内-5-外-挖环化在60 °C 以良好的总产率形成取代的 2-茚满酮。当苄基取代基R 1较大时，1,3-顺式-二取代-2-茚满酮优先形成。取代的茚可以通过霍纳-沃兹沃思-埃蒙斯反应以高产率从 2-茚满酮制备。

  DOI：

  10.1021/jo200271s

文献信息

• 拮抗NOD1/2受体信号通路的喹唑啉酮类化合物
  申请人：宁波康柏睿格医药科技有限公司

  公开号：CN113354590A

  公开（公告）日：2021-09-07

  本发明公开了拮抗NOD1/2受体信号通路的喹唑啉酮类化合物，具体公开了一类的如通式I和II所示的喹唑啉酮类化合物小分子化合物，这类喹唑啉酮类化合物的制备方法，含有这些化合物的药物组合物，以及这类化合物通过拮抗NOD1/2信号传导通路的激活，可用于机体的免疫治疗，尤其是可以用于肿瘤的治疗，属于医药技术领域。
• Glycerol conversion to high-value chemicals: the implication of unnatural α-amino acid syntheses using natural resources
  作者：Yun Ji Park、Jung Woon Yang

  DOI：10.1039/c9gc00755e

  日期：——

  oxidised to produce a high-value compound in high yield using a NaOtBu-O2 system. Furthermore, the synthetic utility of the resulting product was demonstrated by its transformation into unnatural α-amino acids, thus showing the valorisation of glycerol biomass.

  甘油衍生物是一类重要的化合物，作为有机合成中的基本结构基石具有很大的应用前景。使用NaO t Bu-O 2系统将O-苄基甘油氧化以高收率生产高价值的化合物。此外，通过将其转化为非天然的α-氨基酸证明了所得产物的合成效用，从而表明了甘油生物质的增值。
• Novel compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same
  申请人：Amorepacific Corporation

  公开号：EP1857440A1

  公开（公告）日：2007-11-21

  This present invention relates to novel compounds, isomer thereof or pharmaceutically acceptable salts thereof as vanilloid receptor (Vanilloid Receptor 1; VR1; TRPV1) antagonist; and a pharmaceutical composition containing the same. The present invention provides a pharmaceutical composition for preventing or treating a disease such as pain, migraine, arthralgia, neuralgia, neuropathies, nerve injury, skin disorder, urinary bladder hypersensitiveness, irritable bowel syndrome, fecal urgency, a respiratory disorder, irritation of skin, eye or mucous membrane, stomach-duodenal ulcer, inflammatory diseases, ear disease, and heart disease.

  本发明涉及作为类香草素受体（Vanilloid Receptor 1; VR1; TRPV1）拮抗剂的新型化合物、其异构体或其药学上可接受的盐；以及含有这些化合物的药物组合物。 本发明提供了一种药物组合物，用于预防或治疗疼痛、偏头痛、关节痛、神经痛、神经病变、神经损伤、皮肤病、膀胱过敏、肠易激综合征、便急、呼吸系统疾病、皮肤、眼睛或粘膜刺激、胃十二指肠溃疡、炎症性疾病、耳病和心脏病等疾病。
• [3,3]-Sigmatropic Rearrangement/5-<i>exo</i>-<i>dig</i> Cyclization Reactions of Benzyl Alkynyl Ethers: Synthesis of Substituted 2-Indanones and Indenes
  作者：Armen A. Tudjarian、Thomas G. Minehan

  DOI：10.1021/jo200271s

  日期：2011.5.6

  Substituted benzyl alkynyl ethers, prepared from the corresponding α-alkoxy ketones in a two-step sequence involving enol triflate formation and KOtBu-induced E2 elimination, undergo [3,3]-sigmatropic rearrangement/intramolecular 5-exo-dig cyclization at 60 °C to form substituted 2-indanones in good overall yields. 1,3-cis-Disubstituted-2-indanones are formed preferentially when the benzylic substituent

  取代的苄基的炔醚，从在两步骤序列相应的α -烷氧基酮涉及烯醇三氟甲磺酸形成和KO制备吨卜诱导E2消除，经历[3,3] -sigmatropic重排/分子内-5-外-挖环化在60 °C 以良好的总产率形成取代的 2-茚满酮。当苄基取代基R 1较大时，1,3-顺式-二取代-2-茚满酮优先形成。取代的茚可以通过霍纳-沃兹沃思-埃蒙斯反应以高产率从 2-茚满酮制备。
• Discovery of 1,4-Benzodiazepine-2,5-dione (BZD) Derivatives as Dual Nucleotide Binding Oligomerization Domain Containing 1/2 (NOD1/NOD2) Antagonists Sensitizing Paclitaxel (PTX) To Suppress Lewis Lung Carcinoma (LLC) Growth in Vivo
  作者：Suhua Wang、Jingshu Yang、Xueyuan Li、Zijie Liu、Youzhen Wu、Guangxu Si、Yiran Tao、Nan Zhao、Xiao Hu、Yao Ma、Gang Liu

  DOI：10.1021/acs.jmedchem.7b00608

  日期：2017.6.22

  Nucleotide-binding oligomerization domain-like receptors (NLRs) are intracellular sensors of pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs). Previously, we reported nucleotide-binding oligomerization domain-containing protein 1 (NOD1) antagonists (II, 12) and a NOD2 antagonist (9) that sensitized docetaxel (DTX) or paclitaxel (PTX) treatment for breast or lung cancer. In this article, we describe for the first time a 1,4-benzodiazepine-2,5-dione (BZD) derivative (26bh) that acts as a dual NOD1/NOD2 antagonist and inhibits both nuclear factor kappa B (NF-kappa B) and mitogen-activated protein kinase (MAPK) inflammatory signaling, thereby sensitizing PTX to suppress Lewis lung carcinoma (LLC) growth. After investigation of the compound's cytotoxicity, a systematic structure-activity relationship (SAR) was completed and revealed several key factors that were necessary to maintain antagonistic ability. This study establishes the possibility for using adjuvant treatment to combat cancer by antagonizing both NOD1 and NOD2 signaling.